MCID: LFR001
MIFTS: 75

Li-Fraumeni Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Endocrine diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Li-Fraumeni Syndrome

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Li-Fraumeni Syndrome:

Name: Li-Fraumeni Syndrome 52 11 71 23 48 24 25 54 70 12 50 39 13 68
Sbla Syndrome 11 23 48 25
Li-Fraumeni Syndrome 2 70 27 68
Sarcoma Family Syndrome of Li and Fraumeni 48 25
Li-Fraumeni Syndrome 1 27 68
Li Fraumeni Syndrome 48 27
Lfs 25 70
Sarcoma, Breast, Leukemia, and Adrenal Gland Syndrome 25
 
Sarcoma, Breast, Leukaemia and Adrenal Gland Syndrome 11
Li-Fraumeni Familiar Cancer Susceptibility Syndrome 11
Renal-Coloboma Syndrome 24
Papillorenal Syndrome 68
Pillorenal Syndrome 24
Lfs2 70
Lfs1 48

Characteristics:

Orphanet epidemiological data:

54
li-fraumeni syndrome:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (United Kingdom),1-9/100000 (United States); Age of onset: All ages; Age of death: any age

HPO:

64

GeneReviews:

23
Penetrance: lfs is a highly penetrant cancer syndrome. the risks for cancer in lfs are estimated to be 50% by age 30 years and 90% by age 60 years [lustbader et al 1992]. however, men with lfs may have significantly lower lifetime risks of cancer than women [wu et al 2006] (see clinical description). these figures may still be somewhat biased, since individuals are typically offered tp53 testing if they are diagnosed with cancer at unusually young ages...


Classifications:



External Ids:

Disease Ontology11 DOID:3012
MeSH39 D016864
NCIt45 C3476
Orphanet54 ORPHA524
SNOMED-CT62 428850001
MESH via Orphanet40 D016864
UMLS via Orphanet69 C0085390
ICD10 via Orphanet31 D48.9

Summaries for Li-Fraumeni Syndrome

About this section
UniProtKB/Swiss-Prot:70 Li-Fraumeni syndrome: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Li-Fraumeni syndrome 2: A highly penetrant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.

MalaCards based summary: Li-Fraumeni Syndrome, also known as sbla syndrome, is related to adrenal cortical carcinoma and gastric cancer, and has symptoms including acute leukemia, lymphoma and neoplasm of the pancreas. An important gene associated with Li-Fraumeni Syndrome is TP53 (Tumor Protein P53), and among its related pathways are PLK3 signaling events and Proteolysis Putative SUMO-1 pathway. Affiliated tissues include breast, brain and adrenal gland, and related mouse phenotypes are Decreased sensitivity to paclitaxel and Apoptosis resistance.

Disease Ontology:11 An autosomal dominant disease characterized by increases risk of developing several types of cancer, including breast cancer, osteosarcomata and soft tissue sarcomata.

Genetics Home Reference:25 Li-Fraumeni syndrome is a rare disorder that greatly increases the risk of developing several types of cancer, particularly in children and young adults.

OMIM:52 Li-Fraumeni syndrome (LFS) is a clinically and genetically heterogeneous inherited cancer syndrome. LFS is... (151623) more...

NIH Rare Diseases:48 Li-Fraumeni syndrome (LFS) is an inherited condition that is characterized by an increased risk for certain types of cancer. Affected people often develop cancer at an earlier age than expected and may be diagnosed with more than one cancer during their lifetime. LFS is primarily associated with sarcomas (cancers of muscle, bone or connective tissue), breast cancer, brain tumors, leukemia and adrenocortical carcinoma; however, many other types of cancer have been reported in people with this condition. It is caused by changes (mutations) in the TP53 gene and is inherited in an autosomal dominant manner. Management may include high-risk cancer screening and/or prophylactic surgeries. Last updated: 5/4/2015

Wikipedia:71 Li–Fraumeni syndrome is a rare cancer predisposition hereditary disorder characterized as autosomal... more...

Description from OMIM:52 609265

GeneReviews for NBK1311

Related Diseases for Li-Fraumeni Syndrome

About this section

Diseases in the Li-Fraumeni Syndrome family:

Li-Fraumeni Syndrome 3 Li-Fraumeni Syndrome, Chek2-Related

Diseases related to Li-Fraumeni Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 198)
idRelated DiseaseScoreTop Affiliating Genes
1adrenal cortical carcinoma32.1BAX, BCL2, CDKN2A, EGFR, TP53
2gastric cancer31.1BCL2, CDKN2A, TP53
3leiomyosarcoma30.8BRCA1, BRCA2, TP53
4gliosarcoma29.6CDKN1A, CDKN2A, EGFR, IDH1, MDM2, PTEN
5prostate cancer27.7ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
6lung cancer27.5ATM, BAX, BCL2, CAV1, CDKN1A, CDKN2A
7breast cancer26.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
8colorectal cancer26.5BAX, BCL2, BRCA1, BRCA2, CAV1, CDKN1A
9li-fraumeni syndrome 312.2
10li-fraumeni syndrome, chek2-related12.2
11papillorenal syndrome12.0
12lujan-fryns syndrome11.3
13lujan syndrome11.2
14lassa fever11.1
15gastric cancer, somatic11.1
16liddle syndrome, scnn1g-related10.8CHEK2, TP53
17salivary gland adenoid cystic carcinoma10.8CDKN2A, TP53
18chromosome 7p duplication10.8MDM2, TP53
19biliary papillomatosis10.8CDKN2A, TP53
20congenital pulmonary veins atresia or stenosis10.7BRCA1, BRCA2
21peptic ulcer disease10.7EGFR, TP53
22karak syndrome10.7CDKN2A, PTEN
23epidural spinal canal angiolipoma10.7CDKN2A, MDM2
24bronchopulmonary dysplasia10.7BRCA1, BRCA2
25cutaneous lupus erythematosus10.6BRCA1, BRCA2
26autoimmune disease of blood10.6BRCA1, BRCA2
27pasli disease10.6MDM2, TP53
28selective ige deficiency disease10.6BRCA1, BRCA2
29esophagus verrucous carcinoma10.6CDKN2A, PTEN, TP53
30pleuropulmonary blastoma type 210.6CDKN2A, MDM2, PTEN
31familial breast cancer10.6BRCA1, BRCA2, CHEK2
32split hand split foot malformation autosomal recessive10.6CDKN2A, TP53
33cervical serous adenocarcinoma10.6BRCA1, BRCA2, TP53
34breast cancer, childhood10.6BRCA1, BRCA2, CHEK2
35ovarian brenner tumor10.6BRCA1, BRCA2, TP53
36pelvic muscle wasting10.6CDKN2A, PTEN, TP53
37rectum mucinous adenocarcinoma10.6BRCA1, BRCA2, TP53
38vulvar sebaceous carcinoma10.6CDKN1A, MDM2, TP53
39papillary adenofibroma10.6BRCA1, BRCA2, TP53
40herpes simplex10.6CDKN2A, EGFR, TP53
41periodontal disease10.6CDKN2A, MDM2, TP53
42fallopian tube adenosarcoma10.6CDKN2A, MDM2, TP53
43anal squamous cell carcinoma10.6CDKN2A, EGFR, TP53
44fallopian tube germ cell cancer10.6BRCA1, BRCA2, CDKN2A
45actinic keratosis10.6CDKN2A, EGFR, TP53
46cystinosis, nephropathic10.6IDH1, TP53
47integumentary system cancer10.6CDKN2A, EGFR, TP53
48fallopian tube mucinous adenocarcinoma10.6CDKN2A, EGFR, TP53
49lung carcinoma in situ10.6BRCA1, BRCA2, TP53
50maxillary sinus squamous cell carcinoma10.6IDH1, TP53

Graphical network of the top 20 diseases related to Li-Fraumeni Syndrome:



Diseases related to li-fraumeni syndrome

Symptoms & Phenotypes for Li-Fraumeni Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

151623

Clinical features from OMIM:

151623,609265

Human phenotypes related to Li-Fraumeni Syndrome:

 64 54 (show all 26)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 acute leukemia64 hallmark (90%) HP:0002488
2 lymphoma64 54 hallmark (90%) Very frequent (99-80%) HP:0002665
3 neoplasm of the pancreas64 54 hallmark (90%) Very frequent (99-80%) HP:0002894
4 neoplasm of the nervous system64 54 hallmark (90%) Very frequent (99-80%) HP:0004375
5 neoplasm of the skin64 54 hallmark (90%) Very frequent (99-80%) HP:0008069
6 neoplasm of the skeletal system64 hallmark (90%) HP:0010622
7 neoplasm of the breast64 hallmark (90%) HP:0100013
8 sarcoma64 54 hallmark (90%) Very frequent (99-80%) HP:0100242
9 neoplasm of the colon64 54 hallmark (90%) Very frequent (99-80%) HP:0100273
10 neoplasm of the adrenal cortex64 54 hallmark (90%) Very frequent (99-80%) HP:0100641
11 melanoma64 54 occasional (7.5%) Occasional (29-5%) HP:0002861
12 neoplasm of the lung64 occasional (7.5%) HP:0100526
13 nephroblastoma64 HP:0002667
14 osteosarcoma64 54 Very frequent (99-80%) HP:0002669
15 breast carcinoma64 54 Very frequent (99-80%) HP:0003002
16 colon cancer64 HP:0003003
17 adrenocortical carcinoma64 HP:0006744
18 prostate cancer64 HP:0012125
19 lung adenocarcinoma64 HP:0030078
20 soft tissue sarcoma64 HP:0030448
21 prostate neoplasm64 HP:0100787
22 meningioma64 HP:0002858
23 glioma64 HP:0009733
24 stomach cancer64 HP:0012126
25 progressive encephalopathy54 Very frequent (99-80%)
26 neoplasm54 Very frequent (99-80%)

UMLS symptoms related to Li-Fraumeni Syndrome:


joint laxity

GenomeRNAi Phenotypes related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00112-A-010.8NF1, PTEN
2GR00093-A-010.3ATM, CDKN2A, CHEK2, PTEN
3GR00381-A-19.7ATM, CDKN2A, CHEK2, EGFR, NF1
4GR00250-A-37.5ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A
5GR00250-A-15.4ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A

MGI Mouse Phenotypes related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

41 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.1BAX, BCL2, CDKN1A, EGFR, NF1, PAX2
2MP:00053708.7CAV1, CDKN1A, CDKN2A, EGFR, MDM2, NF1
3MP:00053718.6BAX, BRCA1, BRCA2, CDKN1A, EGFR, MDM2
4MP:00011868.6BCL2, BRCA1, CDKN2A, EGFR, MDM2, NF1
5MP:00053808.4ATM, BRCA1, BRCA2, CDKN1A, CDKN2A, EGFR
6MP:00053758.2ATM, BCL2, BRCA1, CAV1, CDKN1A, EGFR
7MP:00053697.7BAX, BCL2, BRCA1, CAV1, CDKN1A, CDKN2A
8MP:00053857.5BCL2, BRCA1, CAV1, CDKN1A, CDKN2A, EGFR
9MP:00053887.5BAX, BCL2, BRCA1, CAV1, CDKN1A, CDKN2A
10MP:00053917.5BAX, BCL2, CDKN1A, CDKN2A, EGFR, MLH1
11MP:00053907.4BAX, BRCA1, BRCA2, CAV1, CDKN1A, CDKN2A
12MP:00053817.1BCL2, BRCA1, BRCA2, CAV1, CDKN1A, CDKN2A
13MP:00053897.1ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
14MP:00053677.1BAX, BCL2, BRCA1, CAV1, CDKN1A, EGFR
15MP:00053796.8ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
16MP:00107716.6ATM, BCL2, BRCA1, BRCA2, CAV1, CDKN1A
17MP:00053876.5ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
18MP:00053976.5ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
19MP:00053866.4ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
20MP:00036316.2ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
21MP:00020066.2ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
22MP:00053845.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
23MP:00053785.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
24MP:00053765.4ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
25MP:00107685.3ATM, BAX, BCL2, BRCA1, BRCA2, CAV1

Drugs & Therapeutics for Li-Fraumeni Syndrome

About this section

Drugs for Li-Fraumeni Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 102)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Trace ElementsPhase 45802
2Anti-Infective AgentsPhase 4, Phase 2, Phase 121402
3
IodinePhase 45467553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
4MicronutrientsPhase 45802
5Anti-Infective Agents, LocalPhase 41785
6cadexomer iodinePhase 4514
7
FluorouracilapprovedPhase 3, Phase 2179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
8
MethotrexateapprovedPhase 315181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
9
Cyclophosphamideapproved, investigationalPhase 3, Phase 2282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
10
LenograstimapprovedPhase 3, Phase 21202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
11
EpirubicinapprovedPhase 338356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
12
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 21918114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
13Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
14Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17171
15AntimetabolitesPhase 3, Phase 2, Phase 111774
16Anti-Bacterial AgentsPhase 3, Phase 210884
17taxanePhase 3344
18Topoisomerase InhibitorsPhase 3, Phase 1, Phase 24945
19Alkylating AgentsPhase 3, Phase 24694
20Antineoplastic Agents, AlkylatingPhase 3, Phase 24474
21Antirheumatic AgentsPhase 3, Phase 210627
22Antimitotic AgentsPhase 3, Phase 25498
23Antibiotics, AntitubercularPhase 3, Phase 26972
24Receptors, Antigen, B-CellPhase 37
25
CisplatinapprovedPhase 2, Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
26
Peginterferon alfa-2bapprovedPhase 1, Phase 230899210-65-8, 215647-85-1
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
 
Peginterferon alfa-2b
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron (TN)
Unitron PEG
27
MesnaapprovedPhase 225819767-45-4, 3375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
2-mercaptoethane sulfonate Na
CoM
Coenzyme M
HS-CoM
28
IsotretinoinapprovedPhase 21184759-48-25538, 5282379
Synonyms:
(13-cis)-Retinoate
(13-cis)-Retinoic acid
(13cis)-retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-retinoic acid
(7e,9e,11e,13Z)-Retinoic acid
13 Cis-Retinoic Acid
13 cis retinoic acid
13-RA
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin A acid
13-cis-Vitamin a acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
CPD000471891
Claravis
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
Isotretinoin (USP)
Isotretinoin Retinoic acid
 
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
LS-143465
Lopac0_001081
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin A acid
Neovitamin a acid
Prestwick2_000256
Prestwick3_000256
Prestwick_642
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 4-3780
Ro 43780
Ro-4-3780
Ro-43780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
SPECTRUM1502013
Sotret
Sotret (TN)
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
cis-RA
cis-Retinoate
cis-Retinoic acid
isotretinoino
29
FludarabineapprovedPhase 2111321679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
30
GemcitabineapprovedPhase 1, Phase 2197495058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
31
Dimethyl sulfoxideapproved, vet_approvedPhase 1, Phase 23367-68-5679
Synonyms:
(CH3)2SO
(methylsulfinyl)methane
DMSO
Dimethyl sulfoxide
Dimethyl sulfoxixde
Dimethyl sulfur oxide
Dimethyl sulphoxide
 
Dimethyl sulpoxide
Dimethyli sulfoxidum
Dimethylsulfoxid
Dimethylsulfoxyde
Dimetil sulfoxido
Methylsulfinylmethane
S(O)Me2
Sulfinylbis(methane)
32
LenalidomideapprovedPhase 2718191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide
33
Capecitabineapproved, investigationalPhase 21296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
34
Dexamethasoneapproved, investigational, vet_approvedPhase 2208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
35
CetuximabapprovedPhase 2737205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
36
AldesleukinapprovedPhase 239785898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
37
Paclitaxelapproved, vet_approvedPhase 2, Phase 1275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
38
CarboplatinapprovedPhase 2, Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
39
EtoposideapprovedPhase 1, Phase 2123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
40
Arsenic trioxideapproved, investigationalPhase 21191327-53-3518740
Synonyms:
28380-38-3
AC1L24QX
AI3-01163
Acide Arsenieux
Acide Arsenieux [French]
Acide arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Anhydride arsenieux [French]
Arseneous anhydride
Arseneous oxide
Arseni Trioxydum
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic Oxidearsenous Trioxide
Arsenic Sesquioxide
Arsenic Trioxide [UN1561] [Poison]
Arsenic blanc [French]
Arsenic oxide
Arsenic oxide (As2O3)
Arsenic sesquioxide
Arsenic trioxide (JP15/USAN)
Arsenic trioxide [JAN]
Arsenic trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic(III) trioxide
Arsenic, White
Arsenicum Album
Arsenicum album
Arsenigen Saure
Arsenigen Saure [German]
Arsenigen saure [German]
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious Trioxide
Arsenious trioxide
Arsenite
Arsenolite
Arsenous Acid
 
Arsenous Acid Anhydride
Arsenous Anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsenous oxide [ISO]
Arsenox
Arsentrioxide
Arsodent
C006632
CCRIS 5455
CHEMBL405991
CID14888
Caswell No. 059
Claudelite
Claudetite
Crude Arsenic
D02106
Di-Arsenic Trioxide
Diarsenic Trioxide
Diarsenic trioxide
Diarsonic Trioxide
EINECS 215-481-4
EPA Pesticide Chemical Code 007001
HSDB 419
LS-761
MolPort-006-823-587
Oxyde Arsenieux
Oxyde Arsenieux [ISO-French]
Poison Flour
RCRA waste no. P012
Rcra waste number P012
Tetraarsenic hexaoxide
Trisenox
Trisenox (TN)
Trixenox
UN 1561
UN1561
UNII-S7V92P67HO
White Arsenic
White arsenic
arsenic trioxide
arsenic(3+)
naonobin
oxygen(2-)
41
Doxorubicinapproved, investigationalPhase 2171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
42
Azacitidineapproved, investigationalPhase 2506320-67-29444
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 AZC
5 Azacytidine
5-AC
5-AZAC
5-AZCR
5-Azacytidine
5-aza-CR
5-azacitidine
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5AzaC
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
 
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
LS-1189
Ladakamycin
Lopac0_000035
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC-102816
NSC102816
Pharmion Brand of Azacitidine
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
SPECTRUM1502111
ST056940
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
Spectrum_001262
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
WR-183027
ZINC03861768
cMAP_000082
mylo sar
pyrimidine antimetabolite: inhibits nucleic acid replication
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
wr 183027
43
Dacarbazineapproved, investigationalPhase 26744342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
44
Temozolomideapproved, investigationalPhase 269385622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
45
Nitroglycerinapproved, investigationalPhase 215055-63-04510
Synonyms:
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetriyl nitrate
100292-13-5
105469-31-6
55-63-0
80066-48-4
8013-23-8
9010-02-0
AC1L1IBV
Adesitrin
Aldonitrin
Angibid
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Anogesic
Aquo-Trimitrosan
BIDD:GT0142
BRN 1802063
Blasting gelatin
Blasting oil
Buccal
Buccard
C07455
C3H5N3O9
CCRIS 4089
CHEBI:28787
CHEMBL730
CID4510
CPD-143
Cardabid
Cardamist
Cardinit
Cardiodisco
Cellegesic
Chitamite
Colenitral
Cordipatch
Corditrine
Coro-Nitro
D00515
D005996
DB00727
Dauxona
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
EINECS 200-240-8
Epinitril
GTN
GTN-Pohl
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
Glycerin trinitrate
Glycerine trinitrate
Glycerintrinitrate
Glycerol trinitrate
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitraat
Glyceroltrinitrat
Glyceryl
Glyceryl nitrate
Glyceryl trinitrate
Glycerylnitrat
Glytrin
HMS2094M15
HSDB 30
Herwicard
Herzer
IMX-150
Klavikordal
LS-7741
Lenitral
Lentonitrina
MED-2002
MQX-503
Mi-Trates
Millisrol
Minitram
Minitran
Minitran (TN)
Minitro
Mionitrat
Myocon
Myoglycerin
Myovin
NG
NITRO IV
NK-843
NTG
Natispray
Neos nitro OPT
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nit-Ret
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nitriderm
Nitriderm TTS
Nitrine-TDC
Nitro Bid
Nitro Dur
Nitro Dur TTS
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitro-Bid
Nitro-Dur 10
Nitro-Dur 5
Nitro-Gesanit Retard
Nitro-M-Bid
Nitro-Mack Retard
Nitro-Par
Nitro-Pflaster
Nitro-Span
Nitro-Time
Nitro-bid (TN)
Nitro-dur
Nitro-dur (TN)
Nitro-lent
NitroBid
NitroCor
 
NitroDur
NitroMist
NitroQuick
NitroQuik
Nitroard
Nitrobaat
Nitrobid Oint
Nitrobukal
Nitrocap
NitrocapT.D
NitrocapT.D.
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
Nitroclyn
Nitrocontin
Nitrocontin Continus
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitroglicerina
Nitrogliceryna
Nitroglin
Nitroglycerin
Nitroglycerin (NG)
Nitroglycerin ointment
Nitroglycerin-ACC
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitroject
Nitrol Ointment
Nitrolan
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitromed
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
Nitromist (TN)
Nitronal Aqueous
Nitronet
Nitrong
Nitrong Retard
Nitrong parenteral
Nitrong-SR
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitroplast
Nitroprol
Nitropront
Nitroprontan
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitrostabilin
Nitrostat
Nitrovis
Nitrozell retard
Nysconitrine
Percutol
Percutol Oint
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Propane-1,2,3-triyl trinitrate
RCRA waste no. P081
Ratiopharm
Rectogesic
SDM No. 17
SK-106N
SK-866
SK-878
Soup
Spirit of glonoin
Susadrin
Suscard
Sustac
Sustak
Sustonit
TNG
Temponitrin
Top-Nitro
Transderm Nitro
Transderm nitro
Transderm-N TTS
Transderm-Nitro TTS
Transderm-nitro
Transderm-nitro (TN)
Transiderm-nitro
Tridil
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, Glyceryl
Trinitrin
Trinitrin Tablets
Trinitrina Erba
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
Trinitrosan
Turicard
UN0143
UN0144
UN1204
UN3064
UN3319
UNII-G59M7S0WS3
Vascana
Vasoglyn
Vasolator
Vernies
Willong
c0061
nitroglycerin
46
Coal tarapprovedPhase 21918007-45-2
Synonyms:
 
Coal tars
Tar, coal
47
Tretinoinapproved, investigational, nutraceuticalPhase 2220302-79-45538
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-trans Retinoic Acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
48
DoxilApproved June 1999Phase 2171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
49HormonesPhase 213979
50Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 212767

Interventional clinical trials:

(show top 50)    (show all 91)
idNameStatusNCT IDPhase
1rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant TumorsUnknown statusNCT00902083Phase 4
2rAd-p53 Gene Therapy for Advanced Malignant Thyroid TumorsUnknown statusNCT00902122Phase 4
3p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced StageUnknown statusNCT00894153Phase 4
4Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknown statusNCT00041613Phase 3
5Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknown statusNCT00041626Phase 3
6Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast CancerCompletedNCT00017095Phase 3
7LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)RecruitingNCT01464086Phase 3
8A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received PrioRecruitingNCT02980731Phase 3
9Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell CarcinomaUnknown statusNCT01574729Phase 2
10Gene Therapy in Treating Patients With Recurrent Head and Neck CancerUnknown statusNCT00003257Phase 2
11Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast CancerUnknown statusNCT00082979Phase 2
12Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell CancerUnknown statusNCT01914900Phase 2
13Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedNCT00064103Phase 1, Phase 2
14Low Dose Arsenic Trioxide as a Potential Chemotherapy ProtectorCompletedNCT01428128Phase 2
15A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)CompletedNCT01357161Phase 2
16Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00049218Phase 1, Phase 2
17Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast CancerCompletedNCT00044993Phase 2
18Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered LymphocytesCompletedNCT00393029Phase 2
19A Study of the Effects of PEITC on Oral Cells With Mutant p53CompletedNCT01790204Phase 1, Phase 2
20Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01459211Phase 2
21A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric CancerCompletedNCT00477711Phase 2
22p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian CancerCompletedNCT00844506Phase 2
23Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian CancerCompletedNCT01639885Phase 1, Phase 2
24QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaCompletedNCT01029873Phase 1, Phase 2
25Oral Isotretinoin Versus Topical Tretinoin for Actinic KeratosisCompletedNCT02278861Phase 2
26Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT02509169Phase 2
27Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT02418988Phase 2
28Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent GlioblastomaRecruitingNCT02340156Phase 2
29Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerRecruitingNCT02340117Phase 2
30ALRN-6924 in Patients With Advanced Solid Tumors or LymphomasRecruitingNCT02264613Phase 1, Phase 2
31Window Trial 5-aza in HNSCC, T-tareRecruitingNCT02178072Phase 2
32Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsRecruitingNCT02593019Phase 2
33Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT02101775Phase 2
34To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic AcidActive, not recruitingNCT00617409Phase 2
35Nitroglycerin in Non-small Cell Lung CancerActive, not recruitingNCT01210378Phase 2
36Transrectal Tumour Oxygen - US ArmyActive, not recruitingNCT00160979Phase 2
37A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)Active, not recruitingNCT01240590Phase 1, Phase 2
38A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerActive, not recruitingNCT01625260Phase 1, Phase 2
39A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerActive, not recruitingNCT01326871Phase 1, Phase 2
40p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular CarcinomaNot yet recruitingNCT02561546Phase 2
41p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT02435186Phase 2
42Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural EffusionNot yet recruitingNCT02429726Phase 2
43P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck CancerNot yet recruitingNCT02429037Phase 2
44Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 MutationNot yet recruitingNCT02688907Phase 2
45S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or ThroatTerminatedNCT00017173Phase 2
46Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung CancerTerminatedNCT00776295Phase 2
47QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01670994Phase 1, Phase 2
48Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction CourseWithdrawnNCT00967512Phase 2
49Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal CancerUnknown statusNCT00003450Phase 1
50The Effects of Hyperbaric Oxygen Therapy (HBOT) on Acute Thermal BurnsUnknown statusNCT00824551Phase 1

Search NIH Clinical Center for Li-Fraumeni Syndrome


Cochrane evidence based reviews: li-fraumeni syndrome

Genetic Tests for Li-Fraumeni Syndrome

About this section

Genetic tests related to Li-Fraumeni Syndrome:

id Genetic test Affiliating Genes
1 Li-Fraumeni Syndrome27 24
2 Li-Fraumeni Syndrome 227
3 Li-Fraumeni Syndrome 127

Anatomical Context for Li-Fraumeni Syndrome

About this section

MalaCards organs/tissues related to Li-Fraumeni Syndrome:

36
Breast, Brain, Adrenal gland, Lung, Bone, Prostate, Liver

Publications for Li-Fraumeni Syndrome

About this section

Articles related to Li-Fraumeni Syndrome:

(show top 50)    (show all 248)
idTitleAuthorsYear
1
Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations. (27726232)
2017
2
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. (27869650)
2017
3
Biochemical and imaging surveillance in Li-Fraumeni syndrome. (27819239)
2016
4
Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. (27984644)
2016
5
Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. (27516001)
2016
6
Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome. (27297285)
2016
7
Genetic and functional analysis of a Li Fraumeni syndrome family in China. (26818906)
2016
8
Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells. (27467582)
2016
9
Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. (26823150)
2016
10
Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome. (27374712)
2016
11
Genetic analysis in a patient with nine primary malignant neoplasms: a rare case of Li-Fraumeni syndrome. (26707089)
2016
12
Breast Cancer in A Nineteen Year Old Adolescent Female identified with Li-Fraumeni Syndrome. (27589880)
2016
13
Li-Fraumeni Syndrome and p53 in 2015: Celebrating their Silver Anniversary. (26833171)
2016
14
Case report of a Li-Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2. (27442652)
2016
15
A rare case of LI-Fraumeni syndrome. (27728568)
2016
16
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. (27496084)
2016
17
Li-Fraumeni syndrome. (27622479)
2016
18
Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply. (27819240)
2016
19
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. (27523101)
2016
20
Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome. (26621765)
2016
21
Does PTEN gene mutation play any role in Li-Fraumeni syndrome. (27493922)
2016
22
Li-Fraumeni Syndrome. (27617148)
2016
23
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. (27501770)
2016
24
The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. (26029016)
2015
25
A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. (25683625)
2015
26
Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome. (26101242)
2015
27
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. (26014290)
2015
28
Radiation therapy for choroid plexus carcinoma patients with Li-Fraumeni syndrome: advantageous or detrimental? (25964589)
2015
29
Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche. (26082798)
2015
30
EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature. (25433984)
2015
31
(18)F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome. (25745605)
2015
32
A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. (25787918)
2015
33
PEComa in a Young Patient with Known Li-Fraumeni Syndrome. (25821471)
2015
34
Caspase Activation and Aberrant Cell Growth in a p53(+/+) Cell Line from a Li-Fraumeni Syndrome Family. (25866679)
2015
35
Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome. (25974645)
2015
36
TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. (25762628)
2015
37
Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy. (26793489)
2015
38
Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome. (25318593)
2014
39
Li-Fraumeni syndrome: cancer risk assessment and clinical management. (24642672)
2014
40
EGFR-mutated lung cancer in Li-Fraumeni syndrome. (25047674)
2014
41
Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. (24573247)
2014
42
Fourth primary malignant tumor in a patient with possible li-fraumeni syndrome: synchronous diagnosis of postirradiation sarcoma, cutaneous relapse of a previous soft tissue sarcoma, and lung adenocarcinoma. (25506014)
2014
43
Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. (24706533)
2014
44
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. (25549704)
2014
45
Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report. (25271877)
2014
46
Li-Fraumeni syndrome: a case report. (25639008)
2014
47
Li-Fraumeni syndrome: multiple distinct brain tumours in two brothers. (24636404)
2014
48
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. (24835218)
2014
49
Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome. (25226867)
2014
50
Atypical fibroxanthoma arising in a young patient with Li-Fraumeni syndrome. (24299451)
2013

Variations for Li-Fraumeni Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Li-Fraumeni Syndrome:

70 (show all 84)
id Symbol AA change Variation ID SNP ID
1CHEK2p.Arg145TrpVAR_008554rs137853007
2TP53p.Met133ThrVAR_005875rs28934873
3TP53p.Ala138ProVAR_005881rs28934875
4TP53p.Cys141TyrVAR_005886rs587781288
5TP53p.Pro151SerVAR_005895rs28934874
6TP53p.Pro151ThrVAR_005896rs28934874
7TP53p.Pro152LeuVAR_005897rs587782705
8TP53p.Arg158GlyVAR_005906
9TP53p.Arg158HisVAR_005907rs587782144
10TP53p.Val173MetVAR_005926
11TP53p.Arg175GlyVAR_005929rs138729528
12TP53p.Arg175LeuVAR_005930rs28934578
13TP53p.Arg175HisVAR_005932rs28934578
14TP53p.His193ArgVAR_005948rs786201838
15TP53p.Arg213GlnVAR_005955rs587778720
16TP53p.Tyr220CysVAR_005957rs121912666
17TP53p.Tyr234CysVAR_005963rs587780073
18TP53p.Met237IleVAR_005965rs587782664
19TP53p.Ser241PheVAR_005969rs28934573
20TP53p.Gly245CysVAR_005972rs28934575
21TP53p.Gly245AspVAR_005973rs121912656
22TP53p.Gly245SerVAR_005974rs28934575
23TP53p.Gly245ValVAR_005975rs121912656
24TP53p.Met246ValVAR_005978rs483352695
25TP53p.Arg248GlnVAR_005983rs11540652
26TP53p.Arg248TrpVAR_005984rs121912651
27TP53p.Leu252ProVAR_005988rs121912653
28TP53p.Glu258LysVAR_005991rs121912652
29TP53p.Val272LeuVAR_005992rs121912657
30TP53p.Arg273CysVAR_005993rs121913343
31TP53p.Arg273GlyVAR_005994
32TP53p.Arg273HisVAR_005995rs28934576
33TP53p.Cys275TyrVAR_005998rs863224451
34TP53p.Pro278LeuVAR_006003
35TP53p.Pro278SerVAR_006004
36TP53p.Pro278ThrVAR_006005
37TP53p.Arg282TrpVAR_006016rs28934574
38TP53p.Arg283CysVAR_006017rs149633775
39TP53p.Glu285GlnVAR_006024
40TP53p.Glu286AlaVAR_006026
41TP53p.Pro309SerVAR_006038
42TP53p.Gly325ValVAR_006039rs28934271
43TP53p.Arg337CysVAR_006041rs587782529
44TP53p.Lys292IleVAR_015819rs121912663
45TP53p.Tyr163CysVAR_033035rs148924904
46TP53p.Arg337HisVAR_035016rs121912664
47TP53p.Arg213ProVAR_036506
48TP53p.Arg273LeuVAR_036509rs28934576
49TP53p.Pro82LeuVAR_044621rs534447939
50TP53p.Gly105CysVAR_044661
51TP53p.Lys132GluVAR_044740rs747342068
52TP53p.Met133ArgVAR_044747
53TP53p.Ala138SerVAR_044764
54TP53p.Gln144LeuVAR_044790
55TP53p.Thr155AsnVAR_044836
56TP53p.Arg156HisVAR_044841rs371524413
57TP53p.Gln167LysVAR_044885
58TP53p.Val172PheVAR_044906
59TP53p.Arg174GlyVAR_044911rs864622115
60TP53p.His179TyrVAR_044939rs587780070
61TP53p.Glu180LysVAR_044943
62TP53p.Arg181CysVAR_044946rs587782596
63TP53p.Arg181HisVAR_044948rs397514495
64TP53p.Arg196ProVAR_045007
65TP53p.Val197MetVAR_045013rs786204041
66TP53p.Ser227ThrVAR_045151
67TP53p.His233AspVAR_045175
68TP53p.Asn235SerVAR_045186rs144340710
69TP53p.Tyr236CysVAR_045189
70TP53p.Cys238GlyVAR_045200
71TP53p.Cys238SerVAR_045202
72TP53p.Gly244AspVAR_045232rs28934572
73TP53p.Gly244ValVAR_045236
74TP53p.Ile251MetVAR_045258
75TP53p.Leu257GlnVAR_045284rs28934577
76TP53p.Leu265ProVAR_045321
77TP53p.Arg267GlnVAR_045330rs587780075
78TP53p.Arg282GlyVAR_045384rs28934574
79TP53p.Arg290HisVAR_045411rs55819519
80TP53p.Arg290LeuVAR_045412
81TP53p.Arg306ProVAR_045475
82TP53p.Leu344ProVAR_045546rs121912662
83TP53p.Ser241ThrVAR_047183
84TP53p.Asp281AsnVAR_047202rs764146326

Clinvar genetic disease variations for Li-Fraumeni Syndrome:

5 (show all 65)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.742C> T (p.Arg248Trp)SNVLikely pathogenic, Pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_000546.5(TP53): c.772G> A (p.Glu258Lys)SNVPathogenicrs121912652GRCh37Chr 17, 7577509: 7577509
3TP53NM_000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
4TP53NM_000546.5(TP53): c.755T> C (p.Leu252Pro)SNVPathogenicrs121912653GRCh37Chr 17, 7577526: 7577526
5TP53NM_000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
6TP53NM_000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
7TP53NM_000546.5(TP53): c.743G> A (p.Arg248Gln)SNVLikely pathogenic, Pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
8TP53NM_000546.5(TP53): c.398T> C (p.Met133Thr)SNVPathogenicrs28934873GRCh37Chr 17, 7578532: 7578532
9TP53NM_000546.5(TP53): c.814G> T (p.Val272Leu)SNVPathogenicrs121912657GRCh37Chr 17, 7577124: 7577124
10TP53TP53, 1-BP INS, 151CinsertionPathogenicChr na, -1: -1
11TP53NM_000546.5(TP53): c.627_628delAA (p.Asn210Hisfs)deletionPathogenicrs587776768GRCh37Chr 17, 7578221: 7578222
12TP53NM_000546.5(TP53): c.844C> T (p.Arg282Trp)SNVPathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
13TP53NM_000546.5(TP53): c.733G> A (p.Gly245Ser)SNVLikely pathogenic, Pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
14TP53NM_000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
15TP53NM_000546.5(TP53): c.974G> T (p.Gly325Val)SNVPathogenicrs121912659GRCh37Chr 17, 7576872: 7576872
16TP53TP53, 1-BP DEL, CODON 257deletionPathogenicChr na, -1: -1
17TP53NM_000546.5(TP53): c.524G> A (p.Arg175His)SNVPathogenicrs28934578GRCh37Chr 17, 7578406: 7578406
18TP53NM_000546.5(TP53): c.1031T> C (p.Leu344Pro)SNVPathogenicrs121912662GRCh37Chr 17, 7573996: 7573996
19TP53NM_000546.5(TP53): c.412G> C (p.Ala138Pro)SNVPathogenicrs28934875GRCh37Chr 17, 7578518: 7578518
20TP53NM_000546.5(TP53): c.532delC (p.His178Thrfs)deletionPathogenicrs863223300GRCh38Chr 17, 7675080: 7675080
21TP53NM_000546.5(TP53): c.875A> T (p.Lys292Ile)SNVPathogenicrs121912663GRCh37Chr 17, 7577063: 7577063
22TP53NM_000546.5(TP53): c.1010G> A (p.Arg337His)SNVPathogenicrs121912664GRCh37Chr 17, 7574017: 7574017
23TP53TP53, 11-BP DEL/5-BP INSindelPathogenicChr na, -1: -1
24TP53NM_000546.5(TP53): c.566C> T (p.Ala189Val)SNVPathogenicrs121912665GRCh37Chr 17, 7578283: 7578283
25TP53NM_000546.5(TP53): c.659A> C (p.Tyr220Ser)SNVPathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
26TP53NM_000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVLikely pathogenic, Pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
27TP53NM_000546.5(TP53): c.701A> G (p.Tyr234Cys)SNVLikely pathogenic, Pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
28TP53NM_000546.5(TP53): c.869G> A (p.Arg290His)SNVPathogenicrs55819519GRCh37Chr 17, 7577069: 7577069
29TP53NM_000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
30PAX2NM_003990.4(PAX2): c.561delC (p.Asn188Metfs)deletionPathogenicrs77777862GRCh37Chr 10, 102541067: 102541067
31PAX2NM_003990.4(PAX2): c.130_151del22 (p.Leu44Profs)deletionPathogenicrs76675173GRCh37Chr 10, 102509589: 102509610
32PAX2PAX2, 6-BP DELdeletionPathogenicChr na, -1: -1
33PAX2NM_003990.4(PAX2): c.226G> A (p.Gly76Ser)SNVPathogenicrs79555199GRCh37Chr 10, 102510464: 102510464
34PAX2NM_000278.3(PAX2): c.221_226dupAGACCG (p.Thr75_Gly76insGluThr)duplicationPathogenicrs387906530GRCh37Chr 10, 102510459: 102510464
35PAX2NM_003990.4(PAX2): c.76delG (p.Val26Cysfs)deletionPathogenicrs75462234GRCh37Chr 10, 102509535: 102509535
36PAX2NM_003990.4(PAX2): c.75_76dupGG (p.Val26Glyfs)duplicationPathogenicrs77453353GRCh37Chr 10, 102509534: 102509535
37PAX2NM_003990.4(PAX2): c.1023C> A (p.Tyr341Ter)SNVPathogenicrs78122364GRCh37Chr 10, 102584439: 102584439
38PAX2PAX2, 1318C-TSNVPathogenicChr na, -1: -1
39TP53NM_000546.5(TP53): c.766A> G (p.Thr256Ala)SNVLikely pathogenicrs587781433GRCh38Chr 17, 7674197: 7674197
40TP53NM_000546.5(TP53): c.1101-2A> GSNVPathogenicrs587781664GRCh37Chr 17, 7573010: 7573010
41TP53NM_000546.5(TP53): c.473G> A (p.Arg158His)SNVLikely pathogenic, Pathogenicrs587782144GRCh37Chr 17, 7578457: 7578457
42TP53NM_000546.5(TP53): c.916C> T (p.Arg306Ter)SNVPathogenicrs121913344GRCh38Chr 17, 7673704: 7673704
43TP53NM_000546.5(TP53): c.542G> A (p.Arg181His)SNVLikely pathogenic, Pathogenicrs397514495GRCh37Chr 17, 7578388: 7578388
44TP53NM_000546.5(TP53): c.455C> T (p.Pro152Leu)SNVPathogenicrs587782705GRCh38Chr 17, 7675157: 7675157
45PAX2NM_003990.4(PAX2): c.76dupG (p.Val26Glyfs)duplicationPathogenicrs77453353GRCh38Chr 10, 100749778: 100749778
46TP53NM_000546.5(TP53): c.267delC (p.Ser90Profs)deletionLikely pathogenicrs587783062GRCh38Chr 17, 7676102: 7676102
47TP53NM_001126115.1(TP53): c.318T> G (p.Cys106Trp)SNVPathogenicrs193920789GRCh38Chr 17, 7674249: 7674249
48TP53NM_000546.5(TP53): c.375G> A (p.Thr125=)SNVPathogenicrs55863639GRCh37Chr 17, 7579312: 7579312
49TP53NM_000546.5(TP53): c.709A> G (p.Met237Val)SNVPathogenicrs730882004GRCh38Chr 17, 7674254: 7674254
50TP53NM_000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVLikely pathogenic, Pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
51TP53NM_000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
52TP53NM_000546.5(TP53): c.672+1G> ASNVPathogenicrs863224499GRCh38Chr 17, 7674858: 7674858
53TP53NM_000546.5(TP53): c.973G> T (p.Gly325Ter)SNVPathogenicrs863224500GRCh37Chr 17, 7576873: 7576873
54TP53NM_000546.5(TP53): c.273G> A (p.Trp91Ter)SNVPathogenicrs876660548GRCh37Chr 17, 7579414: 7579414
55TP53NM_000546.5(TP53): c.-202-?_*1207+?deldeletionPathogenicChr na, -1: -1
56TP53NM_000546.5(TP53): c.662delA (p.Glu221Glyfs)deletionPathogenicrs878854071GRCh38Chr 17, 7674869: 7674869
57TP53NM_000546.5(TP53): c.673-1G> TSNVPathogenicrs878854073GRCh37Chr 17, 7577609: 7577609
58TP53NM_000546.5(TP53): c.845G> A (p.Arg282Gln)SNVPathogenicrs730882008GRCh38Chr 17, 7673775: 7673775
59TP53NM_000546.5(TP53): c.586C> T (p.Arg196Ter)SNVPathogenicrs397516435GRCh37Chr 17, 7578263: 7578263
60TP53NM_000546.5(TP53): c.637C> T (p.Arg213Ter)SNVPathogenicrs397516436GRCh37Chr 17, 7578212: 7578212
61TP53NM_000546.5(TP53): c.817C> T (p.Arg273Cys)SNVLikely pathogenic, Pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
62CHEK2CHEK2, 1-BP DEL, 1100CdeletionPathogenic, risk factorChr na, -1: -1
63CHEK2NM_007194.3(CHEK2): c.470T> C (p.Ile157Thr)SNVLikely pathogenic, Pathogenic, risk factorrs17879961GRCh37Chr 22, 29121087: 29121087
64CHEK2NM_007194.3(CHEK2): c.433C> T (p.Arg145Trp)SNVLikely pathogenic, Pathogenicrs137853007GRCh37Chr 22, 29121242: 29121242
65CHEK2CHEK2, 1-BP DEL, 1422TdeletionPathogenicChr na, -1: -1

Cosmic variations for Li-Fraumeni Syndrome:

8 (show top 50)    (show all 57)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1745010MYOD1soft tissue,striated muscle,rhabdomyosarcoma,NSc.365T>Gp.L122R5
2COSM585NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.183A>Tp.Q61H5
3COSM12475CDKN2Asoft tissue,striated muscle,rhabdomyosarcoma,NSc.238C>Tp.R80*5
4COSM584NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.182A>Gp.Q61R5
5COSM13016PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.226G>Cp.E76Q5
6COSM564NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Ap.G12D5
7COSM580NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.181C>Ap.Q61K5
8COSM13014PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.214G>Ap.A72T5
9COSM14271PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.1508G>Tp.G503V5
10COSM483HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Tp.G12V5
11COSM1651691ALKsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3830T>Cp.I1277T5
12COSM521KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Ap.G12D5
13COSM480HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Ap.G12S5
14COSM11081TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.733G>Tp.G245C5
15COSM45255TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.668C>Gp.P223R5
16COSM45256TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.871A>Cp.K291Q5
17COSM496HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.181C>Ap.Q61K5
18COSM959249DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5125G>Ap.D1709N5
19COSM775PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3140A>Gp.H1047R5
20COSM5664CTNNB1soft tissue,striated muscle,rhabdomyosarcoma,NSc.121A>Gp.T41A5
21COSM10813TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.394A>Gp.K132E5
22COSM574NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.38G>Tp.G13V5
23COSM3744763DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5428G>Tp.D1810Y5
24COSM959251DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5113G>Ap.E1705K5
25COSM3738459DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5437G>Ap.E1813K5
26COSM569NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Cp.G13R5
27COSM516KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Tp.G12C5
28COSM486HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Cp.G13R5
29COSM13013PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.205G>Ap.E69K5
30COSM476BRAFsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1799T>Ap.V600E5
31COSM553KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.182A>Tp.Q61L5
32COSM5692CTNNB1soft tissue,striated muscle,rhabdomyosarcoma,NSc.134C>Ap.S45Y5
33COSM4169595DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5425G>Ap.G1809R5
34COSM532KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.38G>Ap.G13D5
35COSM44536TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.728T>Cp.M243T5
36COSM3738549DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5365-1G>Tp.?5
37COSM45253TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.611A>Gp.E204G5
38COSM45005TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.739A>Gp.N247D5
39COSM481HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Tp.G12C5
40COSM10660TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.818G>Ap.R273H5
41COSM562NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Tp.G12C5
42COSM3738451DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5439G>Tp.E1813D5
43COSM763PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1633G>Ap.E545K5
44COSM760PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1624G>Ap.E542K5
45COSM528KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Ap.G13S5
46COSM586NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.183A>Cp.Q61H5
47COSM766PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1636C>Ap.Q546K5
48COSM1235326PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3023C>Tp.S1008F5
49COSM522KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Cp.G12A5
50COSM143842ALKsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3673G>Ap.D1225N5

Copy number variations for Li-Fraumeni Syndrome from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
111639317650000010700000Copy numberTP53Li-fraumeni syndrome
21179911775058217531588DeletionTP53Li-fraumeni syndrome
31181091775717207590863Copy numberTP53Li-fraumeni syndrome
4162983222350000025900000Copy numberLi-fraumeni syndrome

Expression for genes affiliated with Li-Fraumeni Syndrome

About this section
Search GEO for disease gene expression data for Li-Fraumeni Syndrome.

Pathways for genes affiliated with Li-Fraumeni Syndrome

About this section

Pathways related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 73)
idSuper pathwaysScoreTop Affiliating Genes
110.1CHEK2, TP53
2
Show member pathways
9.9CHEK2, MDM2, TP53
39.9BRCA1, MDM2, TP53
49.9CDKN2A, MDM2, TP53
59.9CDKN2A, MDM2, TP53
69.9CDKN2A, MDM2, TP53
7
Show member pathways
9.9ATM, CHEK2, TP53
89.8ATM, BRCA1, TP53
99.8ATM, BRCA1, TP53
109.8ATM, CDKN1A, TP53
119.8ATM, BRCA1, CDKN1A
129.7BAX, BCL2
139.7BAX, CDKN1A, TP53
14
Show member pathways
9.7ATM, CHEK2, MDM2, TP53
15
Show member pathways
9.6ATM, BRCA1, CHEK2, TP53
16
Show member pathways
9.6BRCA1, CDKN1A, CDKN2A, CHEK2
179.6BCL2, BRCA1, CDKN1A
18
Show member pathways
9.6CDKN1A, EGFR, MDM2, TP53
19
Show member pathways
9.6BCL2, CHEK2, MLH1
209.6ATM, CDKN1A, MDM2, TP53
219.6ATM, BRCA1, CDKN1A, TP53
22
Show member pathways
9.6ATM, CDKN1A, CDKN2A, TP53
239.5BCL2, BRCA1, NF1
24
Show member pathways
9.5ATM, BRCA1, BRCA2, MLH1
259.5BAX, CDKN1A, MDM2, TP53
269.5BCL2, CDKN1A, MDM2, TP53
27
Show member pathways
9.4ATM, BRCA1, BRCA2, CHEK2, TP53
28
Show member pathways
9.4ATM, CDKN2A, CHEK2, MDM2, TP53
299.4CDKN1A, CDKN2A, EGFR, MDM2, TP53
30
Show member pathways
9.4CDKN1A, EGFR, MDM2, PTEN, TP53
31
Show member pathways
9.4ATM, CDKN1A, CDKN2A, MDM2, TP53
329.4EGFR, IDH1, PTEN, TP53
339.3BAX, BCL2, PTEN, TP53
34
Show member pathways
9.3ATM, CDKN1A, EGFR, MDM2, PTEN
359.3BAX, CDKN1A, CDKN2A, MDM2, TP53
36
Show member pathways
9.3BAX, CDKN1A, MDM2, PTEN, TP53
379.2ATM, BAX, BCL2, CHEK2
389.2ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
39
Show member pathways
9.2ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
40
Show member pathways
9.2ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
41
Show member pathways
9.2ATM, CDKN1A, CDKN2A, CHEK2, MDM2, TP53
42
Show member pathways
9.2BRCA2, CDKN1A, CDKN2A, EGFR, MDM2, TP53
439.2BAX, CDKN1A, EGFR, MLH1, TP53
449.1CAV1, CDKN1A, EGFR, MDM2, TP53
45
Show member pathways
9.1BRCA1, CDKN2A, MDM2, TP53, XPC
46
Show member pathways
9.0CAV1, CDKN1A, EGFR, MDM2, PTEN
479.0ATM, BAX, CDKN1A, CDKN2A, CHEK2, TP53
489.0BCL2, CDKN1A, CDKN2A, MDM2, PTEN, TP53
49
Show member pathways
9.0BAX, BCL2, BRCA1, CDKN1A, EGFR
508.8CDKN1A, CDKN2A, EGFR, MDM2, NF1, PTEN

GO Terms for genes affiliated with Li-Fraumeni Syndrome

About this section

Cellular components related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:004693010.3BAX, BCL2
2protein complexGO:00432349.0BRCA1, BRCA2, CAV1, MDM2, PAX2, TP53
3nucleoplasmGO:00056548.7ATM, BRCA1, BRCA2, CDKN1A, CHEK2, MDM2
4cytoplasmGO:00057377.1ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A
5nucleusGO:00056346.8ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A

Biological processes related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 63)
idNameGO IDScoreTop Affiliating Genes
1chordate embryonic developmentGO:004300910.8BRCA1, BRCA2
2chromosome breakageGO:003105210.8BRCA1, BRCA2
3DNA damage induced protein phosphorylationGO:000697510.8ATM, CHEK2
4forebrain morphogenesisGO:004885310.7NF1, PTEN
5meiotic telomere clusteringGO:004514110.7ATM, MLH1
6DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.7BRCA1, BRCA2, TP53
7double-strand break repairGO:000630210.7BRCA1, BRCA2, CHEK2
8cellular response to drugGO:003569010.7CHEK2, EGFR, TP53
9intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:004277110.6BRCA2, CDKN1A, TP53
10regulation of synaptic transmission, GABAergicGO:003222810.6NF1, PTEN
11regulation of mitochondrial membrane permeabilityGO:004690210.6BCL2, TP53
12DNA synthesis involved in DNA repairGO:000073110.6ATM, BRCA1, BRCA2
13double-strand break repair via homologous recombinationGO:000072410.6ATM, BRCA1, BRCA2
14double-strand break repair via nonhomologous end joiningGO:000630310.5ATM, BRCA1, MLH1
15cell agingGO:000756910.5BCL2, BRCA2, TP53
16leukocyte homeostasisGO:000177610.5BAX, BCL2
17intrinsic apoptotic signaling pathwayGO:009719310.5BAX, CDKN1A, TP53
18regulation of cell-matrix adhesionGO:000195210.5BCL2, NF1
19positive regulation of developmental pigmentationGO:004808710.4BAX, BCL2
20negative regulation of reactive oxygen species metabolic processGO:200037810.4BCL2, BRCA1, PAX2
21regulation of nitrogen utilizationGO:000680810.4BAX, BCL2
22regulation of protein heterodimerization activityGO:004349710.4BAX, BCL2
23regulation of protein homodimerization activityGO:004349610.4BAX, BCL2
24cell cycle arrestGO:000705010.4ATM, CDKN1A, CDKN2A, TP53
25negative regulation of fibroblast proliferationGO:004814710.4BAX, NF1, TP53
26negative regulation of G1/S transition of mitotic cell cycleGO:200013410.4BCL2, CDKN1A, PTEN
27cellular response to organic substanceGO:007131010.3BAX, BCL2, MDM2
28cellular senescenceGO:009039810.3CAV1, CDKN1A, CDKN2A
29brain developmentGO:000742010.3ATM, BRCA1, BRCA2, NF1
30response to ionizing radiationGO:001021210.3ATM, BAX, BRCA1
31cellular response to hypoxiaGO:007145610.3BCL2, MDM2, PTEN, TP53
32Ras protein signal transductionGO:000726510.2CDKN1A, CDKN2A, NF1, TP53
33response to X-rayGO:001016510.2BRCA2, CDKN1A, TP53
34heart developmentGO:000750710.2ATM, MDM2, NF1, PTEN
35nucleotide-excision repairGO:000628910.2BRCA2, TP53, XPC
36response to estradiolGO:003235510.2BRCA1, BRCA2, EGFR, PTEN
37negative regulation of cell growthGO:003030810.2BCL2, CDKN1A, CDKN2A, TP53
38neuron apoptotic processGO:005140210.2ATM, BAX, BCL2
39extrinsic apoptotic signaling pathway via death domain receptorsGO:000862510.2BAX, BCL2, NF1
40regulation of signal transduction by p53 class mediatorGO:190179610.1ATM, BRCA1, CHEK2, MDM2, TP53
41replicative senescenceGO:009039910.1ATM, CDKN1A, CDKN2A, CHEK2, TP53
42positive regulation of neuron apoptotic processGO:004352510.1ATM, BAX, NF1, TP53
43protein sumoylationGO:001692510.0BRCA1, MDM2, TP53, XPC
44response to steroid hormoneGO:004854510.0BCL2, IDH1, MDM2
45positive regulation of cell proliferationGO:00082849.9BCL2, EGFR, MDM2, PAX2, PTEN
46response to nutrientGO:00075849.9BRCA1, BRCA2, CAV1, PTEN
47response to UV-BGO:00102249.9BCL2, XPC
48response to organic cyclic compoundGO:00140709.9CDKN1A, EGFR, IDH1, PTEN
49positive regulation of apoptotic processGO:00430659.9ATM, BAX, NF1, PTEN, TP53
50DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:00069779.8ATM, BAX, CDKN1A, CHEK2, MDM2, TP53

Molecular functions related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.8CDKN1A, CDKN2A
2BH3 domain bindingGO:005143410.4BAX, BCL2
3protein phosphatase bindingGO:001990310.3BCL2, EGFR, TP53
4damaged DNA bindingGO:000368410.2BRCA1, TP53, XPC
5enzyme bindingGO:00198999.6BRCA1, CAV1, EGFR, MDM2, PTEN, TP53
6protein kinase bindingGO:00199019.5CAV1, CDKN2A, CHEK2, EGFR, PTEN, TP53
7protein heterodimerization activityGO:00469829.4BAX, BCL2, CAV1, EGFR, TP53
8identical protein bindingGO:00428028.9BAX, BCL2, CAV1, CHEK2, EGFR, MDM2
9ubiquitin protein ligase bindingGO:00316258.8BCL2, BRCA1, CDKN1A, CHEK2, EGFR, MDM2

Sources for Li-Fraumeni Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet